Atea Pharmaceuticals Inc
NASDAQ:AVIR
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Atea Pharmaceuticals Inc
NASDAQ:AVIR
|
331.3m USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
985.1B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
554.2B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
281B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
217.7B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
224.3B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
281.3B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.6T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
150.9B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
97.3B EUR |
Loading...
|
Market Distribution
Other Profitability Ratios
Atea Pharmaceuticals Inc
Glance View
Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 59 full-time employees. The company went IPO on 2020-10-30. The firm is focused on discovering, developing, and commercializing antiviral therapeutics to enhance the lives of patients suffering from life-threatening viral infections. The firm is engaged in the development of product candidates to treat COVID-19, hepatitis C virus (HCV), dengue and respiratory syncytial virus (RSV). The firm is developing bemnifosbuvir (AT-527), which is an investigational, novel, orally administered guanosine nucleotide analog polymerase inhibitor for the treatment of COVID-19. The company is developing bemnifosbuvir and ruzasvir, an investigational nonstructural protein 5A (NS5A) inhibitor for the treatment of chronic HCV infection. The firm is also developing AT-752, an oral, purine nucleotide prodrug for the treatment of dengue. AT-527 is designed to inhibit viral replication by interfering with viral RNA polymerase.
